Section 9: Pharmacovigilance Committee

9. Pharmacovigilance Committee (1) There shall be a Pharmacovigilance Committee which shall consist of— (a) a Chairperson, who shall be a specialist in internal medicine and a public officer; (b) a specialist in paediatrics; (c) a specialist in dermatology; (d) a clinical pharmacologist or a senior lecturer in pharmacology at the University of Mauritius; (e) 2 hospital pharmacists, who shall be public officers; (f) an occupational physician; (g) a nursing officer holding a BSc degree in Nursing or an equivalent qualification; (h) the Chief Pharmacy Dispenser. (2) The Chairperson and every other member, other than an ex officio member, shall— (a) be appointed by the Minister on such terms and conditions as he thinks fit; and (b) hold office for a period of 2 years and be eligible for reappointment. (3) Every member shall be paid such fees or allowances as the Minister may determine. C25A – 9 [Issue 4] Clinical Trials Act (4) The Pharmacovigilance Committee may, where it deems necessary, co-opt other members but any co-opted member shall have no right to vote. (5) (a) Where the Chairperson is absent from any meeting, the members present shall elect from amongst themselves a member to preside at the meeting. (b) At a meeting of the Pharmacovigilance Committee, 5 members shall constitute a quorum. (c) A decision of the Pharmacovigilance Committee shall be by a simple majority of the members present and voting and, in the event of an equality of votes, the Chairperson shall have a casting vote. (d) Subject to this Act, the Pharmacovigilance Committee may conduct its meetings and proceedings in such manner as it thinks fit. (6) The supervising officer may designate such number of public officers as the Pharmacovigilance Committee may require to assist it in the performance of its functions.